Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This study design is a randomized, double-blind, intra-individual controlled, single-center,
phase 1 healthy volunteer study. Subjects who voluntarily signed the informed consent and are
judged to be eligible for this study will be intramuscularly injected with the study drug or
the comparator at a randomized unit(2U, 5U, 10U, 20U, 30U) in each site of the Extensor
digirotum brevis. Thereafter, follow-up visits will be made 14 days, 30days, 60days, 90days
and pharmacodynamic and safety assessments will be conducted for total 90days.
Phase:
Phase 1
Details
Lead Sponsor:
Medy-Tox
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A onabotulinumtoxinA